Multistep mechanism of probiotic bacterium, the effect on innate immune system

Molecular Nutrition and Food Research

Volumn 54, Issue 2, 2010, Pages 277-284

  Amit Romach, Einat ^a   Uni, Zehava ^a   Reifen, Ram ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Experimental colitis; Gene expression; Inflammatory bowel disease; Microbiota; Probiotics

Indexed keywords

AUTACOID; BETA DEFENSIN; BETA DEFENSIN 2, RAT; BETA-DEFENSIN-2, RAT; MESSENGER RNA; MUC2 PROTEIN, RAT; MUCIN 2; PROBIOTIC AGENT; TLR2 PROTEIN, RAT; TLR4 PROTEIN, RAT; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ANIMAL; ARTICLE; BIFIDOBACTERIUM; CHEMICALLY INDUCED DISORDER; COLITIS; COLON; COMPARATIVE STUDY; ENTERITIS; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; LACTOBACILLUS; MALE; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; RANDOMIZATION; RAT; STREPTOCOCCUS; WISTAR RAT;

ANIMALS; BETA-DEFENSINS; BIFIDOBACTERIUM; COLITIS; COLON; GENE EXPRESSION REGULATION; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; LACTOBACILLUS; MALE; MUCIN-2; NEUTROPHIL INFILTRATION; PROBIOTICS; RANDOM ALLOCATION; RATS; RATS, WISTAR; RNA, MESSENGER; STREPTOCOCCUS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

ANIMALIA; BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; RATTUS; STREPTOCOCCUS THERMOPHILUS;

EID: 76749125943     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200800591     Document Type: Article

References (42)

1. Colombel, J. F., Lemann, M., Cassagnou, M., Bouhnik, Y. et al., A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am. J. Gastroenterol. 1999, 94, 674-678.
2. Sartor, R. B., Enteric microflora in IBD: pathogens or commensals? Inflamm. Bowel Dis. 1997, 23-35.
3. Collier-Hyams, L. S., Neish, A. S., Intestinal epithelial barrier and mucosal immunity. Innate immune relationship between commensal flora and the mammalian intestinal epithelium. Cell. Mol. Life Sci. 2005, 62, 1339-1348.
4. Sellon, R. K., Tonkonogy, S., Schultz, M., Dieleman, L. A. et al., Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 1998, 66, 5224-5231.
5. Rioux, K. P., Madsen, K. L., Fedorak, R. N., The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. Gastroenterol. Clin. North Am. 2005, 34, 465-482, ix.
6. Yan, F., Polk, D. B., Commensal bacteria in the gut: learning who our friends are. Curr. Opin. Gastroenterol. 2004, 20, 565-571.
7. Benno, P., Leijonmarck, C. E., Monsen, U., Uribe, A., Midtvedt, T., Functional alterations of the microflora in patients with ulcerative colitis. Scand. J. Gastroenterol. 1993, 28, 839-844.
8. Berrebi, D., Languepin, J., Ferkdadji, L., Foussat, A. et al., Cytokines, chemokine receptors, and homing molecule distribution in the rectum and stomach of pediatric patients with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 2003, 37, 300-308.
9. Sartor, R. B., Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126, 1620-1633.
10. Marteau, P., Shanahan, F., Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract. Res. Clin. Gastroenterol. 2003, 17, 725-740.
11. Thompson-Chagoyan, O. C., Maldonado, J., Gil, A., Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin. Nutr. 2005, 24, 339-352.
12. Swidsinski, A., Ladhoff, A., Pernthaler, A., Swidsinski, S. et al., Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122, 44-54.
13. Ott, S. J., Musfeldt, M., Wenderoth, D. F., Hampe, J. et al., Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004, 53, 685-693.
14. Fabia, R., Ar'Rajab, A., Johansson, M. L., Andersson, R. et al., Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 1993, 54, 248-255.
15. Peran, L., Sierra, S., Comalada, M., Lara-Villoslada, F. et al., A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br. J. Nutr. 2007, 97, 96-103.
16. Rioux, K. P., Fedorak, R. N., Probiotics in the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 2006, 40, 260-263.
17. Food and Agriculture Organization of the United Nations, Organization W.H., Guidelines for the Evaluation of Probiotics in Food, London, Ontario, Canada 2002.
18. Peluso, I., Fina, D., Caruso, R., Stolfi, C. et al., Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation. Infect. Immun. 2007, 75, 1730-1737.
19. Resta-Lenert, S., Barrett, K. E., Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003, 52, 988-997.
20. Amit-Romach, E., Uni, Z., Reifen, R., Therapeutic potential of two probiotics in inflammatory bowel disease as observed in the trinitrobenzene sulfonic acid model of colitis. Dis. Colon Rectum 2008, 51, 1828-1836.
21. Ghadimi, D., Folster-Holst, R., de Vrese, M., Winkler, P. et al., Effects of probiotic bacteria and their genomic DNA on TH1/TH2-cytokine production by peripheral blood mononuclear cells (PBMCs) of healthy and allergic subjects. Immunobiology 2008, 213, 677-692.
22. Guarino, M. P., Altomare, A., Stasi, E., Marignani, M. et al., Effect of acute mucosal exposure to Lactobacillus rhamnosus GG on human colonic smooth muscle cells. J. Clin. Gastroenterol. 2008, 42, S185-S190.
23. Jurjus, A. R., Khoury, N. N., Reimund, J. M., Animal models of inflammatory bowel disease. J. Pharmacol. Toxicol. Methods 2004, 50, 81-92.
24. Morris, G. P., Beck, P. L., Herridge, M. S., Depew, W. T. et al., Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96, 795-803.
25. Dieleman, L. A., Palmen, M. J., Akol, H., Bloemena, E. et al., Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 1998, 114, 385-391.
26. Pfaffl, M. W., A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29, e45.
27. Madsen, K. L., Doyle, J. S., Jewell, L. D., Tavernini, M. M., Fedorak, R. N., Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999, 116, 1107-1114.
28. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., Medzhitov, R., Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118, 229-241.
29. Venkatraman, A., Ramakrishna, B. S., Pulimood, A. B., Patra, S., Murthy, S., Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate. Scand. J. Gastroenterol. 2000, 35, 1053-1059.
30. Lee, Y. K., Puong, K. Y., Ouwehand, A. C., Salminen, S., Displacement of bacterial pathogens from mucus and Caco-2 cell surface by lactobacilli. J. Med. Microbiol. 2003, 52, 925-930.
31. Marteau, P. R., de Vrese, M., Cellier, C. J., Schrezenmeir, J., Protection from gastrointestinal diseases with the use of probiotics. Am. J. Clin. Nutr. 2001, 73, 430S-436S.
32. Salminen, S. J., Gueimonde, M., Isolauri, E., Probiotics that modify disease risk. J. Nutr. 2005, 135, 1294-1298.
33. Roessler, A., Friedrich, U., Vogelsang, H., Bauer, A. et al., The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention. Clin. Exp. Allergy 2008, 38, 93-102.
34. Olivares, M., Diaz-Ropero, M. P., Gomez, N., Lara-Villoslada, F. et al., The consumption of two new probiotic strains, Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711, boosts the immune system of healthy humans. Int. Microbiol. 2006, 9, 47-52.
35. Miettinen, M., Lehtonen, A., Julkunen, I., Matikainen, S., Lactobacilli and Streptococci activate NF-kappa B and STAT signaling pathways in human macrophages. J. Immunol. 2000, 164, 3733-3740.
36. Isolauri, E., Kirjavainen, P. V., Salminen, S., Probiotics: A role in the treatment of intestinal infection and inflammation? Gut 2002, 50, III54-III59.
37. Marteau, P., Pochart, P., Bouhnik, Y., Rambaud, J. C., The fate and effects of transiting, nonpathogenic microorganisms in the human intestine. World Rev. Nutr. Diet 1993, 74, 1-21.
38. Radeva, G., Buyse, M., Hindlet, P., Beaufils, B. et al., Regulation of the oligopeptide transporter, PEPT-1, in DSS-induced rat colitis. Dig. Dis. Sci. 2007, 52, 1653-1661.
39. Strup-Perrot, C., Vozenin-Brotons, M. C., Vandamme, M., Benderitter, M., Mathe, D., Expression and activation of MMP -2, -3, -9, -14 are induced in rat colon after abdominal X-irradiation. Scand. J. Gastroenterol. 2006, 41, 60-70.
40. Nakao, A., Moore, B. A., Murase, N., Liu, F. et al., Immunomodulatory effects of inhaled carbon monoxide on rat syngeneic small bowel graft motility. Gut 2003, 52, 1278-1285.
41. Plaisancie, P., Ducroc, R., El Homsi, M., Tsocas, A. et al., Luminal leptin activates mucin-secreting goblet cells in the large bowel. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G805-G812.
42. Le Mandat Schultz, A., Bonnard, A., Barreau, F., Aigrain, Y. et al., Expression of TLR-2, TLR-4, NOD2 and pNF-kappaB in a neonatal rat model of necrotizing enterocolitis. PLoS ONE 2007, 2, e1102.